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Introduction
The interleukin (IL)-1 family of cytokines encompasses a
wide spectrum of soluble mediators and receptor antago-
nists. Their expression, present in nearly all organ systems,
is of particular importance at mucosal barriers interfacing
the external microenvironment, such as the skin, the res-
piratory tract, and the gastrointestinal (GI) system. IL-1
and IL-1-related cytokines are key factors in the promotion,
enhancement, and regulation of host innate immunity and
in the orchestration of their interplay with the adaptive
immune system. Interestingly, several IL-1 family mem-
bers, including IL-1a/IL-1b, IL-18, and IL-33, display
dichotomous, opposing functions in the pathogenesis of
chronic intestinal inflammation, by both inducing inflam-
mation and promoting epithelial restitution/repair and
mucosal healing [1]. Emerging evidence, however, sug-
gests that the IL-1 family member 7 (IL-1F7), also termed
IL-37, possesses predominant and seemingly exclusive
anti-inflammatory activities, particularly in the setting of
inflammatory bowel disease (IBD) and other colitic
conditions.
Discovery and Characterization of IL-37
Although the existence of IL-1F7 was discovered in 2000
by in silico studies, the mediator only began to be char-
acterized in terms of its structure, function, and biology a
decade later and was subsequently named IL-37 [2].
Seminal studies clearly reported that IL-37 dampens both
innate and adaptive immune responses, thus reducing
general inflammation; indeed, IL-37, when present during
Toll-like/IL-1 receptor stimulation or uric acid sensing,
greatly reduces the synthesis of many proinflammatory
cytokines [2, 3]. Consistent with these findings, experi-
ments utilizing several different animal models support the
concept that IL-37 is protective toward inflammatory
conditions, such as endotoxic shock, myocardial infarction,
metabolic syndrome, asthma, acute lung injury, and
ischemic liver disease [3].
With regard to chronic inflammatory conditions of the
GI tract, IL-37 reduces the severity of dextran sulfate
sodium (DSS)-induced colitis in mice through decreased
colonic production of IL-1b and tumor necrosis factor
(TNF), increased IL-10 secretion, and an overall reduction
in the number of CD4?IFNc? T lymphocytes [4, 5].
Interestingly, experiments using this model of acute colitis
indicate that, from a functional point of view, the most
important cellular sources of IL-37 are of hematopoietic
and mesenchymal origin [4]. Of note, however, is that mice
appear to lack the IL-37 gene [3]. As such, experiments
utilizing mouse models of disease, including experimental
colitides, have been conducted using IL-37 transgenic
mice, genetically engineered to express human IL-37 [4],
or normal rodents injected with mesenchymal stromal cells
transfected with the human IL-37 gene [5]. Indeed, while
these studies provide important insight into IL-37 function,
these results should be interpreted with caution, bearing in
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mind that alternative cellular sources of IL-37 may also
contribute substantially to its immunoregulatory activities
in the GI tract.
Concepts and Controversies Surrounding
the Function of IL-37 During Chronic Intestinal
Inflammation
The study from Gunaltay et al. [6], published in the current
issue of Digestive Diseases and Sciences, explores the
possibility that colonic epithelial-derived IL-37 promotes
the maintenance of intestinal immune homeostasis through
the downregulation of gut proinflammatory molecules.
Using CRISPR/Cas9 technology in a human colonic
epithelial cell line, the authors demonstrate that even a
modest reduction in IL-37 expression augments production
of chemokines following activation of the Toll-like
receptor (TLR)5 signaling pathway after exposure to bac-
terial-derived flagellin. These findings are notable since
they once again emphasize the central importance of the
intestinal epithelium in contributing to the regulation of
both innate and adaptive immune responses triggered by
the gut microbiome [7]. Indeed, the intestinal epithelium is
constantly barraged by components of commensal and
pathogenic bacteria, as well as by other potentially harmful
insults. Depending on the immunological status and genetic
predisposition of the host, intestinal epithelial cells respond
by producing several proinflammatory molecules, includ-
ing not only IL-1a, IL-18, and IL-8, and other chemotactic
factors [7], but also anti-inflammatory molecules (e.g., IL-
1Ra, IL-11) that counterbalance innate mucosal immune
activation, as it appears to be the case for IL-37.
An additional point to note is that the results reported in
Gunaltay et al. [6] are consistent and in line with this
group’s prior study, describing reduced IL-37 expression
and increased chemokine concentrations in colonic biop-
sies from patients affected by microscopic colitides [8].
Microscopic colitides (MC) including collagenous colitis
and lymphocytic colitis feature inappropriate immune
activation of the colonic mucosa, characterized by rich
lymphocytic infiltrates within the lamina propria and
intraepithelial space, with a predominance of cytotoxic
CD8? cells, and myeloid cells, such as eosinophils and
macrophages [9]. Currently, the pathogenesis and etiology
of MC are still not completely understood. The present
study performed by Gunaltay et al. [6] puts forth an
intriguing hypothesis in that, whatever the etiology may be,
a general reduction of epithelial-derived IL-37 drives
epithelial cells themselves to respond in an exaggerated
manner to components of the gut microbiome, specifically
TLR5 ligands, by producing an overabundance of proin-
flammatory molecules. Eventually, this cascade of events
triggers and/or perpetuates a detrimental mucosal immune
activation and contributes to the specific pathogenesis of
MC.
It is also important to consider that studies reporting IL-
37 expression in the colonic mucosa of IBD patients are
conflicting. Ulcerative colitis and Crohn’s disease, the two
main idiopathic forms of IBD, are chronic, relapsing
inflammatory conditions of the gut, characterized by acute
and chronic immune cell infiltrates in the epithelium [7]. In
the previously cited manuscript from Gunaltay et al. [8],
IL-37 was decreased during active ulcerative colitis and
upregulated when disease was quiescent, consistent with its
anti-inflammatory activities. Nevertheless, studies per-
formed in a pediatric IBD patient population reported
intense immunostaining for IL-37 localized to epithelial
cells and lymphoid infiltrates in the gut mucosa of affected
individuals, and increased IL-37 mRNA transcripts, which
together, correlated with disease severity [10]. Yet another
study showed elevated IL-37 concentrations, detected by
flow cytometry, in circulating B cells, natural killer lym-
phocytes, and monocytes from adult IBD patients [11].
These discrepancies may not be surprising, considering the
different patient populations (adult vs. pediatric), cell types
(epithelial vs. immune cells; mucosal vs. circulating
immune cells), and disease status (active vs. quiescent)
evaluated in these studies.
Finally, and to add further complexity to the under-
standing of IBD pathogenesis, IL-37 likely exerts its bio-
logical effects through two different mechanisms. Il-37 can
bind to IL-18Ra, subsequently dimerizing with IL-1R8/
SIGIRR (as opposed to IL-18Rb that initiates IL-18 signal-
ing); this IL-18Ra/IL-1R8 complex then recruits and inhibits
the proinflammatory adaptor protein,MyD88, preventing the
activation of downstream NF-jB-dependent events [12].
Alternatively, (and similar to IL-1a and IL-33), IL-37 may
serve as an intracellular nuclear factor, directly binding to
DNA elements and downregulating transcription of proin-
flammatory mediators. In order for nuclear translocation to
occur, IL-37 requires the presence of phosphorylated-
SMAD3 protein [2]. Importantly, IBD patients usually have
elevated gut mucosal levels of SMAD7 at initial evaluation
[13], which block the anti-inflammatory activities of trans-
forming growth factor (TGF)b through potent inhibition of
SMAD3 phosphorylation [14]. A recent phase II trial using
an antisense oligonucleotide that blocks SMAD7 revealed a
significant clinical benefit in IBDpatients, demonstrating the
importance of SMAD7 in the pathogenesis of IBD [15].
Therefore, similarly to TGFb, although IL-37 may be highly
expressed in IBD, its anti-inflammatory activity may be
prevented due to elevated concentrations of SMAD7 in the
local intestinal mucosa of IBD patients. Future studies in this
area of investigation are warranted since the extent of
SMAD7-mediated blockade of IL-37 is still unknown,
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particularly regarding the relative contribution of IL-18Ra/
IL-1R8- and phospho-SMAD3-mediated modulation of IL-
37 activity.
Conclusion
The manuscript by Gunaltay and colleagues published in
the current issue of Digestive Diseases and Sciences pro-
vides new insight into the potential mechanism(s) of
chronic inflammatory conditions of the GI tract, such as
MC and IBD. In particular, the presence of IL-37, appar-
ently central to the regulation of intestinal immune
homeostasis at the epithelial barrier by responding to
bacterial sensing specifically through TLR5, may be
required to prevent dysregulation of normal gut immu-
nity (Fig. 1). Indeed, most IL-1 family members when
produced by the epithelium (vs. immune cells) during early
innate events possess protective functions in the regulation
of the interplay between the host and the gut microbiome
[1, 7]. In individuals unable to mount appropriate immune
responses against harmful factors, perhaps due to deficits in
IL-37 production, a homeostatic imbalance can ensue that
promotes chronic intestinal inflammation (Fig. 1).
Still, many issues need to be addressed in order to fur-
ther define the precise function of IL-37 in the GI tract. The
lack of a murine homologue will certainly challenge sci-
entists to use innovative approaches and models other than
those traditionally used to dissect the in vivo function of
other pro-/anti-inflammatory molecules and IL-1 family
members. Furthermore, the relative importance of the two
different mechanisms of action of IL-37 should also be
clarified. Finally, further identification of specific endoge-
nous and exogenous factors able to regulate IL-37
expression in diverse cell types within the intestinal
mucosa is of particular relevance in order to better under-
stand the etiopathogenetic processes of MC and IBD.
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Fig. 1 Working hypothesis of the functions of epithelial-derived IL-
37 during chronic intestinal inflammation. Intestinal epithelial cells
(IEC) sense commensal bacteria or pathogens, which can penetrate
the gut barrier, especially during pathogenic disease states, and gain
access to basolaterally expressed innate, Toll-like receptors (TLRs),
including TLR5, which recognize bacterial components, such as
flagellin. TLR5-flagellin engagement activates the adapter protein,
MyD88, triggering NF-jB nuclear translocation and downstream
production of chemokines and other proinflammatory cytokines.
a During homeostatic conditions, healthy IEC express high levels of
intracellular IL-37 that bind to phosphorylated (P)-SMAD3 and
translocate to the nucleus, inhibiting the production of chemokines
and proinflammatory cytokines. Secreted IL-37 can also bind to IL-
18Ra, recruiting IL-1R8/SIGGR to form the IL-18Ra/IL-1R8 dimer,
which sequesters MyD88 and prevents its activation. b When IL-37
levels are reduced, NF-jB is free to translocate to the nucleus;
alternatively, increased SMAD7 inhibits SMAD3 phosphorylation,
which may prevent subsequent IL-37/SMAD3 nuclear translocation.
In both circumstances, production of chemokines and proinflamma-
tory cytokines is no longer inhibited. The result is uncontrolled
recruitment and activation of innate immune cells with subsequent
amplification of adaptive immune responses leading to chronic
intestinal inflammation, such as that observed in MC and IBD
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